Crovalimab Monthly Subcutaneous Injection Approved for PNH: 94% Breakthrough Hemolysis Control

What Is Crovalimab and How Does It Improve PNH Treatment?

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening blood disease in which the complement system destroys red blood cells. Current treatment with eculizumab (Soliris) requires intravenous infusions every two weeks at a hospital or infusion center, imposing a significant burden on PNH patients, who number an estimated 5,000–10,000 in the United States. Crovalimab uses Roche's proprietary recycling antibody technology, developed in collaboration with Chugai Pharmaceutical, which allows each antibody molecule to bind and neutralize multiple C5 molecules sequentially, enabling effective complement inhibition with far less drug and less frequent dosing.

The COMMODORE 1 trial enrolled complement-inhibitor-naive PNH patients, while COMMODORE 2 studied patients switching from eculizumab. In both Phase 3 trials, crovalimab demonstrated non-inferiority to eculizumab on the primary endpoint of hemoglobin stabilization and LDH control. The majority of crovalimab patients achieved hemolysis control (defined as LDH ≤1.5× upper limit of normal), with results comparable to eculizumab. Breakthrough hemolysis events were uncommon in both treatment groups over the 24-week primary analysis period.

How Do Patients Self-Administer Crovalimab at Home?

Crovalimab treatment begins with a loading phase consisting of intravenous and subcutaneous doses administered at a healthcare facility over the first few weeks. From approximately week 4 onward, patients self-administer a subcutaneous injection once every four weeks at home. In clinical trials, the large majority of patients or caregivers were able to successfully perform self-injection after training, demonstrating the feasibility of home-based administration.

The shift from hospital-based to home-based treatment has significant quality-of-life implications. Eculizumab requires approximately 26 infusion center visits per year, each typically lasting several hours including travel and observation time, while crovalimab reduces this to approximately 12 brief home injections annually. In patient-reported outcomes from the COMMODORE trials, crovalimab patients reported meaningful improvements in treatment satisfaction and reduced treatment burden compared to eculizumab. From a cost perspective, complement inhibitor therapies for PNH are among the most expensive treatments in medicine, with eculizumab priced at roughly $500,000 per year. Crovalimab and ravulizumab (Ultomiris), the other approved complement inhibitor given every 8 weeks intravenously, represent alternative options, and competition among these agents may influence pricing over time.